Please wait...


Generic Name: idursulfase (EYE dur SUL fase)
Brand Names: Elaprase
Elaprase is used to treat some of the symptoms of Hunter's syndrome. Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Elaprase

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Elaprase (idursulfase) is an IV infusion used to treat some of the symptoms of a genetic condition called Hunter's syndrome, also called mucopolysaccharidosis (MYOO-koe-pol-ee-SAK-a-rye-DOE-sis). Idursulfase contains a natural enzyme that some people lack because of a genetic disorder. Elaprase helps replace this missing enzyme. Hunter syndrome is a metabolic disorder in which the body lacks the enzyme needed to break down certain sugars and proteins. These substances can build up in the body, causing enlarged organs, abnormal bone structure, changes in facial features, breathing problems, heart problems, vision loss, and changes in mental or physical abilities. Learn more

Elaprase Side Effects

Elaprase Side Effects

Note: This document contains side effect information about idursulfase. Some of the dosage forms listed on this page may not apply to the brand name Elaprase.

In Summary

Common side effects of Elaprase include: abscess, chest wall pain, dyspepsia, infusion related reaction, pruritic rash, pruritus, urticaria, and visual disturbance. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to idursulfase: intravenous solution


Intravenous route (Solution)

Life-threatening anaphylactic reactions, presenting as respiratory distress, hypoxia, hypotension, urticaria, and/or angioedema of throat or tongue have occurred in some patients during and up to 24 hours after idursulfase infusions, regardless of duration of the course of treatment. Closely observe patients during and after idursulfase administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.

Along with its needed effects, idursulfase (the active ingredient contained in Elaprase) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking idursulfase:

More common

  • Bone or muscle pain
  • chest pain
  • chills
  • cough
  • fast, pounding, or irregular heartbeat or pulse
  • feeling of warmth
  • fever
  • headache
  • hives or welts
  • itching
  • rash
  • redness of the face, neck, arms, and occasionally, upper chest
  • redness of the skin
  • sneezing
  • sore throat
  • tightness in the chest
  • unusual tiredness or weakness

Less common

  • Blurred vision
  • confusion
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • sweating

Incidence not known

  • Difficulty with swallowing
  • dilated neck veins
  • extreme fatigue
  • heart stops
  • irregular breathing
  • no breathing
  • no pulse or blood pressure
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • unconscious
  • weight gain

Some side effects of idursulfase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Change in hearing
  • diarrhea
  • ear drainage
  • earache or pain in the ear

Less common

  • Nausea
  • vomiting

For Healthcare Professionals

Applies to idursulfase: intravenous solution


The most frequently reported adverse effects in all clinical trials were hypersensitivity reactions and included rash, urticaria, pruritus, flushing, pyrexia, and headache.

The most frequently reported adverse effects following treatment were hypoxia, pyrexia, rash, vomiting, diarrhea, cough, musculoskeletal pain, headache, pruritus, and urticaria.


In clinical trials, the most common adverse effects were hypersensitivity reactions and included rash, urticaria, pruritus, flushing, pyrexia, and headache. Most reactions were resolved with slowing the infusion rate or temporarily stopping the infusion, with or without additional treatments including antihistamines and/or corticosteroids prior to or during infusions.

Very common (10% or more): Hypersensitivity reaction

Frequency not reported: Anaphylactoid/anaphylactic reaction

Postmarketing reports: Late-emergent anaphylactoid reaction


In clinical trials, 32 out of 63 patients 5 years and older tested positive for antidrug antibodies at least 1 time; of the 32 patients, 23 tested positive for antidrug antibodies 3 or more times. The incidence of hypersensitivity reactions was higher in positive antidrug antibody patients than those who tested negative. Out of 32 antidrug antibody positive patients, 13 also tested positive for neutralizing antibodies. There was no clear relationship between presence of either type of antibody and therapeutic response.

Very common (10% or more): Antidrug antibody development (50%), neutralizing antibody development (24.3%)

Nervous system

Very common (10% or more): Headache (up to 65.6%)

Common (1% to 10%): Dizziness, tremor


Very common (10% or more): Rash (up to 34.4%), pruritus (up to 31.3%), urticaria (up to 16%)

Common (1% to 10%): Erythema


Very common (10% or more): Infusion-related reaction (68.8%), pyrexia (up to 62.5%), chest pain (up to 15.6%), infusion site swelling (12.5%)

Common (1% to 10%): Face edema, peripheral edema

The most serious infusion-related reactions included anaphylactoid/anaphylactic reactions. The most common infusion-related reactions included cutaneous reactions (rash, pruritus, urticaria), pyrexia, headache, hypertension, flushing, wheezing, hypoxia, dyspnea, abdominal pain, nausea, dyspepsia, chest pain, and infusion site swelling. Treatment/amelioration of infusion-related reactions included slowing the infusion rate, interrupting the infusion, or drug therapy (e.g., antihistamines, antipyretics, low-dose corticosteroids [prednisone, methylprednisolone], beta-agonist nebulization).


Very common (10% or more): Musculoskeletal pain (13%)

Common (1% to 10%): Arthralgia


Very common (10% or more): Abdominal pain (up to 53.1%), nausea (up to 28.1%), dyspepsia (12.5%), vomiting, diarrhea

Common (1% to 10%): Swollen tongue


Very common (10% or more): Hypertension (up to 25%), flushing (15.6%)

Common (1% to 10%): Cyanosis, arrhythmia, tachycardia, hypotension

Postmarketing reports: Cardiac failure, cardiorespiratory arrest


Very common (10% or more): Wheezing (15.6%), dyspnea (up to 12.5%)

Common (1% to 10%): Cough, bronchospasm, tachypnea, hypoxia

Frequency not reported: Pulmonary embolism

Postmarketing reports: Respiratory failure, respiratory distress, pneumonia

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Elaprase